3D Marker Supports Breast Cancer Treatment
By MedImaging International staff writers Posted on 04 Dec 2013 |
Image: The BioZorb 3D bioresorbable marker device (Photo courtesy of Focal Therapeutics).
A novel three-dimensional (3D) marker facilitates postsurgical radiation treatment for breast cancer by identifying the surgical site of tumor removal clearly and accurately.
The BioZorb device possesses a unique open-spiral design that incorporates six permanent titanium clips in a 3D fixed arrangement, provides specific landmarks of the surgical site for treatment planning, delivery, and follow-up. Since the BioZorb is sutured directly to the tissues surrounding the cavity where the tumor was removed, it stays in the right spot and enables more precise targeting of the radiation after surgery. Made of a bioabsorbable material, the device is absorbed by the patient's body over time, rather than requiring a surgeon to remove it later.
The BioZorb is especially useful when there is no visible residual seroma; a condition encountered during radiation therapy planning that makes it very difficult to identify the target region. The 3D marker may also assist with patient positioning during treatment, as well as advanced treatment techniques such as image‐guided radiation therapy and image-based tracking of the lumpectomy site during respiratory motion. The BioZorb device is a product of Focal Therapeutics (Portola Valley, CA, USA), and has been approved by the US Food and Drug Administration (FDA).
“This device represents a significant advancement towards the precise delivery of radiation treatment,” said radiation oncologist Robert R. Kuske, Jr., MD, of Arizona Breast Cancer Specialists (Phoenix, USA). “With the BioZorb, we know exactly where to aim the dose, so we can irradiate a smaller amount of tissue. That gives us the ability to get better results with less risk to healthy tissues nearby.”
“The learning curve for placing this device is straightforward, and it fit smoothly into my routine from day one. I've been using it in most of my patients,” said surgical oncologist Michael J. Cross, MD, who was the first US surgeon to place the BioZorb tissue marker. “The best thing about using it is the confidence we have that our patient's tumor site will be well-defined for the radiation oncologist.”
Related Links:
Focal Therapeutics
The BioZorb device possesses a unique open-spiral design that incorporates six permanent titanium clips in a 3D fixed arrangement, provides specific landmarks of the surgical site for treatment planning, delivery, and follow-up. Since the BioZorb is sutured directly to the tissues surrounding the cavity where the tumor was removed, it stays in the right spot and enables more precise targeting of the radiation after surgery. Made of a bioabsorbable material, the device is absorbed by the patient's body over time, rather than requiring a surgeon to remove it later.
The BioZorb is especially useful when there is no visible residual seroma; a condition encountered during radiation therapy planning that makes it very difficult to identify the target region. The 3D marker may also assist with patient positioning during treatment, as well as advanced treatment techniques such as image‐guided radiation therapy and image-based tracking of the lumpectomy site during respiratory motion. The BioZorb device is a product of Focal Therapeutics (Portola Valley, CA, USA), and has been approved by the US Food and Drug Administration (FDA).
“This device represents a significant advancement towards the precise delivery of radiation treatment,” said radiation oncologist Robert R. Kuske, Jr., MD, of Arizona Breast Cancer Specialists (Phoenix, USA). “With the BioZorb, we know exactly where to aim the dose, so we can irradiate a smaller amount of tissue. That gives us the ability to get better results with less risk to healthy tissues nearby.”
“The learning curve for placing this device is straightforward, and it fit smoothly into my routine from day one. I've been using it in most of my patients,” said surgical oncologist Michael J. Cross, MD, who was the first US surgeon to place the BioZorb tissue marker. “The best thing about using it is the confidence we have that our patient's tumor site will be well-defined for the radiation oncologist.”
Related Links:
Focal Therapeutics
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure